**RESULTS**

**Multi-Antigen Vaccine Does Not Occur in PBMCs From Chronic HBV Carriers**

- **Induction of IFN-γ and TNF-α Expression by the Chimigen® HBV Multi-antigen Vaccine in PBMCs From Chronic HBV Carriers**

- **Induction of IFN-γ Secretion by the Chimigen® HBV Multi-antigen Vaccine in PBMCs From Chronic HBV Carriers**

- **Induction of Treg Apoptosis by the Chimigen® HBV Multi-antigen Vaccine in PBMCs From Chronic HBV Carriers**

- **Induction of DC Death by Chimigen® HBV Multi-antigen Vaccine Does Not Occur in the Absence of T Cells.**

**METHODS**

- **T-cell Priming With Vaccine-loaded mDC**

  - Antigen-specific T cells are generated by vaccination with the Chimigen® HBV Multi-antigen Vaccine including S1/S2 and Core peptides. After stimulation in vitro, antigen-specific T cells are isolated and infused into chronically infected HBV patients. T-cell responses are monitored using antigen-specific IFN-γ production.

  - The Chimigen® HBV Multi-antigen Vaccine is prepared using suitable viral antigens that are loaded onto mDC. T cells are isolated from chronic HBV carriers following re-stimulation with the HBV S1/S2 or Core peptides. Each color bar represents one individual donor.

**SUMMARY**

- The Chimigen® HBV Multi-antigen Vaccine is a unique vaccine that can break HBV tolerance in chronic HBV carriers by inducing strong antigen-specific T cells. The vaccine is able to induce a protective immune response against HBV in vivo, and is a promising treatment for chronic HBV infection.

- The vaccine is effective in inducing T-cell responses in chronic HBV carriers, and is able to break HBV tolerance by inducing strong antigen-specific T cells. The vaccine is a promising treatment for chronic HBV infection.

**ACKNOWLEDGMENTS**

- This research was supported by the National Institutes of Health (NIH) grant number 5R01AI109264-03.

HepDART 2011 Frontiers in Drug Development for Viral Hepatitis, December 4-8, 2011 The Grand Hyatt Kauai, Ko'olau Kauai, Hawaii, USA